Monoclonal antibodies and checkpoint inhibitors for multiple myeloma
Efficacy and safety of CD19-targeted CAR T-cells for relapsed/refractory ALL
Frontline therapy for multiple myeloma
iwNHL 2016: Highlights from Day 1
Catherine Bollard et al.
Myeloma 2016: Panel discussion on the new treatment paradigm
Gareth Morgan et al.